Company / Operating Income
Olema Pharmaceuticals, Inc. Operating Income History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$142.3M
FY2024
5-year range
-$142.3M / -$21.5M
FY2020-FY2024
Trend
-35.5%
vs FY2023
Sector context
#110 of 204
Health Care
What the data says
At -$142M, Olema Pharmaceuticals, Inc.'s operating income ranks #110 of 204 in the Health Care sector. Declined from -$107M to -$142M over the past 2 years.
Based on SEC 10-K filings.
-$142M in FY2024.
Declined from -$107M to -$142M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#110 of 204 in Health CareTop 54% of 204This company -$142.3M Sector average $107.7M
▼
-232.1% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 35.5% year-over-year.
- Ranks #110 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$142.3M | -35.5% |
| FY2023 | -$105.0M | +1.9% |
| FY2022 | -$107.0M | -49.7% |
| FY2021 | -$71.5M | -232.1% |
| FY2020 | -$21.5M | -398.0% |
| FY2019 | -$4.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026